Literature DB >> 33115881

A Respiratory Syncytial Virus Attachment Gene Variant Associated with More Severe Disease in Infants Decreases Fusion Protein Expression, Which May Facilitate Immune Evasion.

Stacey Human1,2, Anne L Hotard1,2, Larry J Anderson1,2, Tina V Hartert3,4, Martin L Moore5,2, Christina A Rostad1,2, Sujin Lee1,2, Louise McCormick1,2, Emma K Larkin6,4, Teresa C T Peret7, Jaume Jorba8, Joseph Lanzone1,2, Tebeb Gebretsadik9, John V Williams10, Melissa Bloodworth11, Matthew Stier11, Kecia Carroll4, R Stokes Peebles6,11.   

Abstract

This study identified a genotype of respiratory syncytial virus (RSV) associated with increased acute respiratory disease severity in a cohort of previously healthy term infants. The genotype (2stop+A4G) consists of two components. The A4G component is a prevalent point mutation in the 4th position of the gene end transcription termination signal of the G gene of currently circulating RSV strains. The 2stop component is two tandem stop codons at the G gene terminus, preceding the gene end transcription termination signal. To investigate the biological role of these RSV G gene mutations, recombinant RSV strains harboring either a wild-type A2 strain G gene (one stop codon preceding a wild-type gene end signal), an A4G gene end signal preceded by one stop codon, or the 2stop+A4G virulence-associated combination were generated and characterized. Infection with the recombinant A4G (rA4G) RSV mutant resulted in transcriptional readthrough and lower G and fusion (F) protein levels than for the wild type. Addition of a second stop codon preceding the A4G point mutation (2stop+A4G) restored G protein expression but retained lower F protein levels. These data suggest that RSV G and F glycoprotein expression is regulated by transcriptional and translational readthrough. Notably, while rA4G and r2stop+A4G RSV were attenuated in cells and in naive BALB/c mice compared to that for wild-type RSV, the r2stop+A4G RSV was better able to infect BALB/c mice in the presence of preexisting immunity than rA4G RSV. Together, these factors may contribute to the maintenance and virulence of the 2stop+A4G genotype in currently circulating RSV-A strains.IMPORTANCE Strain-specific differences in respiratory syncytial virus (RSV) isolates are associated with differential pathogenesis in mice. However, the role of RSV genotypes in human infection is incompletely understood. This work demonstrates that one such genotype, 2stop+A4G, present in the RSV attachment (G) gene terminus is associated with greater infant disease severity. The genotype consists of two tandem stop codons preceding an A-to-G point mutation in the 4th position of the G gene end transcription termination signal. Virologically, the 2stop+A4G RSV genotype results in reduced levels of the RSV fusion (F) glycoprotein. A recombinant 2stop+A4G RSV was better able to establish infection in the presence of existing RSV immunity than a virus harboring the common A4G mutation. These data suggest that regulation of G and F expression has implications for virulence and, potentially, immune evasion.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  A4G; G glycoprotein; disease severity; gene end; gene variant; infant; respiratory syncytial virus; tandem stop codons; transcriptional regulation; wheeze

Mesh:

Substances:

Year:  2020        PMID: 33115881      PMCID: PMC7944440          DOI: 10.1128/JVI.01201-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Native immunogold labeling of cell surface proteins and viral glycoproteins for cryo-electron microscopy and cryo-electron tomography applications.

Authors:  Hong Yi; Joshua D Strauss; Zunlong Ke; Eric Alonas; Rebecca S Dillard; Cheri M Hampton; Kristen M Lamb; Jason E Hammonds; Philip J Santangelo; Paul W Spearman; Elizabeth R Wright
Journal:  J Histochem Cytochem       Date:  2015-06-11       Impact factor: 2.479

2.  CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

Authors:  Tatiana Chirkova; Songbai Lin; Antonius G P Oomens; Kelsey A Gaston; Seyhan Boyoglu-Barnum; Jia Meng; Christopher C Stobart; Calvin U Cotton; Tina V Hartert; Martin L Moore; Assem G Ziady; Larry J Anderson
Journal:  J Gen Virol       Date:  2015-06-25       Impact factor: 3.891

3.  Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.

Authors:  Jason S McLellan; Yongping Yang; Barney S Graham; Peter D Kwong
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

4.  Respiratory Syncytial Virus Attachment Glycoprotein Contribution to Infection Depends on the Specific Fusion Protein.

Authors:  Jia Meng; Anne L Hotard; Michael G Currier; Sujin Lee; Christopher C Stobart; Martin L Moore
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

5.  Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.

Authors:  Joan O Ngwuta; Man Chen; Kayvon Modjarrad; M Gordon Joyce; Masaru Kanekiyo; Azad Kumar; Hadi M Yassine; Syed M Moin; April M Killikelly; Gwo-Yu Chuang; Aliaksandr Druz; Ivelin S Georgiev; Emily J Rundlet; Mallika Sastry; Guillaume B E Stewart-Jones; Yongping Yang; Baoshan Zhang; Martha C Nason; Cristina Capella; Mark E Peeples; Julie E Ledgerwood; Jason S McLellan; Peter D Kwong; Barney S Graham
Journal:  Sci Transl Med       Date:  2015-10-14       Impact factor: 17.956

6.  Functional Analysis of the 60-Nucleotide Duplication in the Respiratory Syncytial Virus Buenos Aires Strain Attachment Glycoprotein.

Authors:  Anne L Hotard; Elizabeth Laikhter; Kelsie Brooks; Tina V Hartert; Martin L Moore
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

7.  A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction.

Authors:  Martin L Moore; Michael H Chi; Cindy Luongo; Nicholas W Lukacs; Vasiliy V Polosukhin; Matthew M Huckabee; Dawn C Newcomb; Ursula J Buchholz; James E Crowe; Kasia Goleniewska; John V Williams; Peter L Collins; R Stokes Peebles
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

8.  Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years.

Authors:  E Kathryn Miller; Tebeb Gebretsadik; Kecia N Carroll; William D Dupont; Yassir A Mohamed; Laura-Lee Morin; Luke Heil; Patricia A Minton; Kimberly Woodward; Zhouwen Liu; Tina V Hartert; John V Williams
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

9.  The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection.

Authors:  Kate L Stokes; Michael G Currier; Kaori Sakamoto; Sujin Lee; Peter L Collins; Richard K Plemper; Martin L Moore
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

10.  Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures.

Authors:  Sara M Johnson; Beth A McNally; Ioannis Ioannidis; Emilio Flano; Michael N Teng; Antonius G Oomens; Edward E Walsh; Mark E Peeples
Journal:  PLoS Pathog       Date:  2015-12-11       Impact factor: 6.823

View more
  3 in total

1.  Hydrophilic But Not Hydrophobic Surfactant Protein Genetic Variants Are Associated With Severe Acute Respiratory Syncytial Virus Infection in Children.

Authors:  Lynnlee C Depicolzuane; Catherine M Roberts; Neal J Thomas; Keenan Anderson-Fears; Dajiang Liu; João Paulo Pereira Barbosa; Felipe Rodrigues Souza; André Silva Pimentel; Joanna Floros; Chintan K Gandhi
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

Review 2.  Clinical and biological consequences of respiratory syncytial virus genetic diversity.

Authors:  Estefany Rios Guzman; Judd F Hultquist
Journal:  Ther Adv Infect Dis       Date:  2022-10-08

3.  An approach to lifting self-isolation for health care workers with prolonged shedding of SARS-CoV-2 RNA.

Authors:  H Laferl; H Kelani; T Seitz; B Holzer; I Zimpernik; A Steinrigl; F Schmoll; C Wenisch; F Allerberger
Journal:  Infection       Date:  2020-10-06       Impact factor: 7.455

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.